Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1169
Abstract: Oral pharmacotherapy for overactive bladder, a condition that increases with age, includes anticholinergics and β3‐adrenergic receptor agonists. Older adults, including those with dysphagia, may have difficulty swallowing tablets. In this phase 1 study in healthy… read more here.
Keywords: vibegron; pharmacokinetics safety; tablet; healthy adults ... See more keywords
PD21-02 EFFICACY OF ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) IN OLDER PATIENTS
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000871.02
Abstract: INTRODUCTION AND OBJECTIVE:Vibegron is a novel, once-daily, oral β3-adrenoceptor agonist under development for treatment of OAB. In the phase 3, randomized, double-blind, placebo- and active-contro... read more here.
Keywords: overactive bladder; efficacy daily; pd21 efficacy; daily vibegron ... See more keywords
Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000023171
Abstract: Abstract Background: Vibegron is a new β3-adrenergic receptor agonist which has been demonstrated for the treatment of overactive bladder (OAB). We carried out meta-analysis to evaluate the efficiency of vibegron vs antimuscarinic monotherapy for treating… read more here.
Keywords: vibegron antimuscarinic; vibegron; antimuscarinic monotherapy; meta analysis ... See more keywords
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s310371
Abstract: Abstract Pharmacologic treatment for overactive bladder (OAB), which is characterized by bothersome symptoms such as urgency and urge urinary incontinence (UUI), includes anticholinergics and β3-adrenergic receptor agonists. Anticholinergics are associated with adverse effects including dry… read more here.
Keywords: efficacy safety; treatment; safety vibegron; vibegron ... See more keywords